Stay updated with breaking news from Peter Maag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurologyStrong balance sheet, bolstered by recent public offering, expected to fund operations into...
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered,...
Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.